IM atropine
Phase 2Small molecule
IM atropine is one of 38 small molecule programs targeting Arrhythmia. It is currently in Phase 2.
1
Indications
1
Total Trials
0
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
43 competitors in Arrhythmia
#DrugCompanyPhaseTrials
1Colcrys
Alnylam PharmaceuticalsApproved
Ondexxya
UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
Approved
Betapace
LLegacy Health System
Approved
Lovaza
AstraZenecaApproved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Lanoxin
AAdvanz Pharma
Approved
Ozempic
Novo NordiskPhase 3
Conventional
PPopulation Health Research Institute
Approved
Rythmol Sr
GGlaxo Dba Glaxosmithkline
Approved
Ancef
BBaxter Healthcare Corporation
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Arrhythmia1 trial
Brad Arrhythmia Induced by Repeated Succinylcholine During Gynecological Laparoscopic Surgery
Completed·—·Phase 2·NCT02676011·120 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IM atropine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- AAssiut University